Aria Pharmaceuticals announces positive in vivo data for two idiopathic pulmonary fibrosis candidates August 26, 2021 In the News Small molecule drug developer Aria Pharmaceuticals (Palo Alto, Calif.) has announced that two investigational treatments for idiopathic pulmonary fibrosis (IPF), TXR-1002 and TXR-1007, demonstrated efficacy and tolerability in preclinical research. READ MORE
Aria Pharmaceuticals Presents Positive In Vivo Data Showing Two Novel Treatment Candidates Demonstrated Positive Efficacy and Tolerability in Idiopathic Pulmonary Fibrosis Compared to Standard of Care August 26, 2021 Press Release TXR-1002 and TXR-1007, demonstrated significant efficacy and excellent tolerability in preclinical studies. READ MORE